However, ATRA treatment established a new CRC, no longer including TCF4 and CEBPG or the ADRN TFs PHOX2B, but now driven by core TFs including Retinoic Acid Receptor Alpha (RARA), HIC1, amongst others (Figure 6A). Here, RARA is linked to colorectal carcinoma.